An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

• Status: Completed
• Trial end date: 2019-06-24
• Target enrollment: 0
• Participant gender: All

Summary

This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• BMI ≥ 25 and ≤ 40 kg/m2

Exclusion Criteria:

• Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds)

• Any bone trauma (fracture) or bone surgery (ie, hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration

• Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status

• Any major surgery (eg, abdominal, thoracal, or cranial procedures) within 6 weeks of study drug administration

• Donation of blood or plasma to a blood bank, or in a clinical study (except at the screening visit) within 6 weeks of study drug administration

• Inability to tolerate subcutaneous injections

Other protocol defined inclusion/exclusion criteria could apply